It is a Proactive interview so the questions are not exactly taxing. But the ansswers given by Steve O'Hara of Optibiotix (OPTI) are illuminating. "The majority" of partners are now generating revenues. This company has signed almost 30 deals. That tells me that the massive ramp up in sales in H2 of last year will continue and indeed accelerate in H1 this year and beyond so full steam ahead. I reckon the shares are a buy at the current 84p and at up to 90p and see the shares motoring ahead to 125p+ in short order. Note what O'Hara says about the pipeline of announcements.
on ShareProphets | CommentsFiled under: